6,650 results match your criteria: "Radical Hysterectomy"
Front Med (Lausanne)
December 2024
Department of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Human papillomavirus (HPV)-related multiphenotypic sinonasal carcinoma (HMSC) is a biphasic epithelial tumor associated with HPV infection. This rare tumor primarily affects the nasal cavity and paranasal sinuses, with only two cases reported outside these locations to date-one in the breast and one in the vulva. This report presents a case of a tumor resembling an HMSC arising in the cervix.
View Article and Find Full Text PDFObstet Gynecol
December 2024
National Clinical Research Center for Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Objective: It remains unclear whether modifying laparoscopic radical hysterectomy to adopt tumor-free principles can improve oncologic outcomes in patients with early-stage cervical cancer.
Methods: We performed a single-center retrospective cohort study of 276 patients with early-stage cervical cancer who were treated between January 2017 and January 2023, including 151 patients who underwent laparoscopic radical hysterectomy that incorporated modified tumor-free techniques (MTF group) and 125 patients who underwent conventional laparoscopic radical hysterectomy with a uterine manipulator and unprotected intracorporeal colpotomy (non-MTF group). Oncologic outcomes and perioperative results were analyzed using inverse probability treatment weighting (IPTW).
Cureus
November 2024
Medical Oncology, Tata Main Hospital, Jamshedpur, IND.
World J Surg Oncol
December 2024
Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 # Panjiayuannanli, Chaoyang District, Beijing, 100021, China.
J Obstet Gynaecol Res
January 2025
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
J Med Case Rep
December 2024
Consultant Gynaecology Oncologist, Royal Sussex Hospital, Brighton, UK.
J Med Case Rep
November 2024
Tu Du Clinical Research Unit (TD-CRU), Tu Du Hospital, Ho Chi Minh City, Vietnam.
BMJ Open
November 2024
West China School of Nursing, Sichuan University/Department of Nursing, West China Hospital, Sichuan University, Chengdu, Sichuan, China
J Midlife Health
October 2024
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, Bibinagar, Telangana, India.
J Midlife Health
October 2024
Department of OBGYN, Gandhi Medical College, Hyderabad, Telangana, India.
BMC Cancer
November 2024
Department of Gynecology, Dongguan Tungwah Hospital, Dongguan, China.
Diseases
November 2024
Department of Obstetrics and Gynecology, Toho University Medical Center Sakura, 564-1 Shimoshizu, Sakura City 285-8741, Chiba Prefecture, Japan.
Introduction: Cervical mesonephric ductal adenocarcinoma (MA) is an HPV-independent adenocarcinoma that occurs in middle-aged women. MA originates from remnants of the Wolffian duct that usually regress in females once the induction of sex differentiation is activated. MA is a rare disease that accounts for less than 1% of all cervical adenocarcinomas.
View Article and Find Full Text PDFOnco Targets Ther
November 2024
Department of Obstetrics and Gynecology, Zhabei Centrial Hospital, Jing'an District, Shanghai, 200070, People's Republic of China.
BMJ Open
November 2024
School of Medical Informatics, Chongqing Medical University, Chongqing, China
Acta Obstet Gynecol Scand
November 2024
Department of Reproductive Medicine, Division of Gynecology and Reproduction, Karolinska University Hospital, Stockholm, Sweden.
Am J Dermatopathol
December 2024
Institute of Dermatology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China; and.
Cancer Med
November 2024
Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
J Cancer Res Clin Oncol
November 2024
School of Anesthesiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Eur J Surg Oncol
January 2025
Department of Maternal and Child Health, Obstetrics and Gynecology Clinic, Ospedale Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; PhD School in Biomedical Sciences, Gender Medicine, Child and Women Health, University of Sassari, Sassari, Italy.
Objective: We assessed reproductive, obstetrical, and oncological outcomes in patients who underwent fertility-sparing treatment by including studies that adhere to the FIGO 2018 staging system.
Methods: Data on recurrence, mortality, pregnancy rate, live birth rate, and preterm delivery rate were collected.
Results: In patients with stages IA1, IA2, and IB1, the recurrence rate was 4.
BMC Cancer
November 2024
The Robot Center, Tokyo International Ohori Hospital, 4-8-40, Shimorenjaku, Mitaka City, Tokyo, 181-0013, Japan.
Eur J Radiol
December 2024
Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Biomol Biomed
November 2024
Department of Clinical Laboratory, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.
Int J Cancer
November 2024
Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, The Netherlands.
J Minim Invasive Gynecol
October 2024
Department of Obstetrics and Gynecology, Kurashiki Medical Center, Okayama, Japan (all authors).
Arch Gynecol Obstet
December 2024
School of Medicine, Nankai University, 94 Weijin Road, Tianjin, 300071, China.